Quest Diagnostics Inc vs Google Inc — how do they compare? Quest Diagnostics Inc trades at $204.83 (market cap $22.80B), while Google Inc trades at $367.16 (market cap $4.37T). The key difference: Google Inc is far larger — about 191.7× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| DGX | GOOG | |
|---|---|---|
Market Cap | $22.80B | $4.37T |
Sector | Health | Technology |
52-Week High | $216.02 | $399.06 |
52-Week Low | $166.42 | $183.10 |
Enterprise Value | $28.82B | $4.34T |
Dividend Yield | 1.67% | 0.25% |
Volume | — | 1,511,127 |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Alphabet (GOOG) trades at $350.67, down 1.23% amid bearish technical signals, though fundamentals remain robust with strong earnings beats and 32.8% net margin. Revenue grew to $402.84B in 2025, while analyst consensus is overwhelmingly bullish with an 86.84% buy rating and $457.50 price target. Recent news highlights AI advancements and regulatory scrutiny.
Outlook is positive given earnings momentum and AI leadership, but risks include regulatory probes and high valuation multiples. The stock offers growth potential with disciplined risk management advised amid technical weakness and competitive pressures.
Trailing returns across standard periods
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →